The synthetic peptide P111-136 derived from the C-terminal domain of heparin affin regulatory peptide inhibits tumour growth of prostate cancer PC-3 cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Hamma Kourbali, Yamina ^a   Bermek, Oya ^a   Bernard Pierrot, Isabelle ^a,c   Karaky, Racha ^b   Martel Renoir, Dominique ^b   Frechault, Sophie ^a   Courty, José ^a   Delbé, Jean ^a  

^a Université Paris Est Créteil CNRS ^*  (France)

^b CNRS   (France)

^c INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; MATRIGEL; NUCLEOLIN; P 111-136; PACLITAXEL; PLEIOTROPHIN; SYNDECAN 3; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; CARRIER PROTEIN; CYTOKINE; PEPTIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL LINE; CELL LYSATE; CELL STRAIN PC3; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; NUDE MOUSE; PROSTATE ADENOCARCINOMA; PROTEIN BINDING; PROTEIN DOMAIN; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; FEMALE; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR; SYNTHESIS; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PROSTATIC NEOPLASMS; PROTEIN BINDING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79957570286     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-212     Document Type: Article

References (56)

1. Cunha GR, Donjacour A. Stromal-epithelial interactions in normal and abnormal prostatic development. Prog Clin Biol Res 1987, 239:251-272.
2. Courty J, Milhiet PE, Delbe J, Caruelle D, Barritault D. Heparin-Affin Regulatory Peptide, HARP. Springer 2000,
3. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998, 44(4):705-723.
4. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem (Tokyo) 2002, 132(3):359-371.
5. Pufe T, Bartscher M, Petersen W, Tillmann B, Mentlein R. Expression of pleiotrophin, an embryonic growth and differentiation factor, in rheumatoid arthritis. Arthritis Rheum 2003, 48(3):660-667. 10.1002/art.10839, 12632418.
6. Heroult M, Bernard-Pierrot I, Delbe J, Hamma-Kourbali Y, Katsoris P, Barritault D, Papadimitriou E, Plouet J, Courty J. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene 2004, 23(9):1745-1753. 10.1038/sj.onc.1206879, 15001987.
7. Chauhan AK, Li YS, Deuel TF. Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proceedings of the National Academy of Sciences of the United States of America 1993, 90(2):679-682. 10.1073/pnas.90.2.679, 45727, 8421705.
8. Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. Journal of Biological Chemistry 1992, 267(36):25889-25897.
9. Soulie P, Heroult M, Bernard-Pierrot I, Caruelle D, Oglobine J, Barritault D, Courty J. Correlation of elevated plasma levels of two structurally related growth factors, heparin affin regulatory peptide and midkine, in advanced solid tumor patients. Cancer Detect Prev 2004, 28(5):319-324. 10.1016/j.cdp.2004.03.004, 15542254.
10. Souttou B, Juhl H, Hackenbruck J, Rockseisen M, Klomp HJ, Raulais D, Vigny M, Wellstein A. Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. J Natl Cancer Inst 1998, 90(19):1468-1473. 10.1093/jnci/90.19.1468, 9776412.
11. Vacherot F, Caruelle D, Chopin D, Gil-Diez S, Barritault D, Caruelle JP, Courty J. Involvement of heparin affin regulatory peptide in human prostate cancer. Prostate 1999, 38(2):126-136. 10.1002/(SICI)1097-0045(19990201)38:2<126::AID-PROS6>3.0.CO;2-C, 9973098.
12. Hatziapostolou M, Delbe J, Katsoris P, Polytarchou C, Courty J, Papadimitriou E. Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity. Prostate 2005, 65(2):151-158. 10.1002/pros.20270, 15924335.
13. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, Caughey DJ, Wen D, Karavanov A, Riegel AT, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001, 276(20):16772-16779. 10.1074/jbc.M010660200, 11278720.
14. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263(5151):1281-1284. 10.1126/science.8122112, 8122112.
15. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, Yamamoto T. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997, 14(4):439-449. 10.1038/sj.onc.1200849, 9053841.
16. Peria FM, Neder L, Marie SK, Rosemberg S, Oba-Shinjo SM, Colli BO, Gabbai AA, Malheiros SM, Zago MA, Panepucci RA, et al. Pleiotrophin expression in astrocytic and oligodendroglial tumors and it's correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival. J Neurooncol 2007, 84(3):255-261. 10.1007/s11060-007-9379-2, 17443289.
17. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase (ALK) is rate- limiting for glioblastoma growth. J Biol Chem 2002, 23:23.
18. Maeda N, Noda M. Involvement of receptor-like protein tyrosine phosphatase zeta/RPTP beta and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration. J Cell Biol 1998, 142(1):203-216. 10.1083/jcb.142.1.203, 2133018, 9660874.
19. Polykratis A, Katsoris P, Courty J, Papadimitriou E. Characterization of heparin affin regulatory peptide signaling in human endothelial cells. J Biol Chem 2005, 280(23):22454-22461. 10.1074/jbc.M414407200, 15797857.
20. Meng K, Rodriguez-Pena A, Dimitrov T, Chen W, Yamin M, Noda M, Deuel TF. Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc Natl Acad Sci USA 2000, 97(6):2603-2608. 10.1073/pnas.020487997, 15975, 10706604.
21. Pariser H, Ezquerra L, Herradon G, Perez-Pinera P, Deuel TF. Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem Biophys Res Commun 2005, 332(3):664-669. 10.1016/j.bbrc.2005.05.007, 15925565.
22. Pariser H, Herradon G, Ezquerra L, Perez-Pinera P, Deuel TF. Pleiotrophin regulates serine phosphorylation and the cellular distribution of beta-adducin through activation of protein kinase C. Proc Natl Acad Sci USA 2005, 102(35):12407-12412. 10.1073/pnas.0505901102, 1194948, 16116087.
23. Tamura H, Fukada M, Fujikawa A, Noda M. Protein tyrosine phosphatase receptor type Z is involved in hippocampus-dependent memory formation through dephosphorylation at Y1105 on p190 RhoGAP. Neurosci Lett 2006, 399(1-2):33-38. 10.1016/j.neulet.2006.01.045, 16513268.
24. Perez-Pinera P, Zhang W, Chang Y, Vega JA, Deuel TF. Anaplastic Lymphoma Kinase Is Activated Through the Pleiotrophin/Receptor Protein-tyrosine Phosphatase beta/{zeta} Signaling Pathway: An Alternative Mechanism Of Receptor Tyrosine Kinase Activation. J Biol Chem 2007, 282(39):28683-28690. 10.1074/jbc.M704505200, 17681947.
25. Bernard-Pierrot I, Delbe J, Caruelle D, Barritault D, Courty J, Milhiet PE. The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities. J Biol Chem 2001, 276(15):12228-12234. 10.1074/jbc.M010913200, 11150308.
26. Bernard-Pierrot I, Delbe J, Rouet V, Vigny M, Kerros ME, Caruelle D, Raulais D, Barritault D, Courty J, Milhiet PE. Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities. J Biol Chem 2002, 277(35):32071-32077. 10.1074/jbc.M202747200, 12070152.
27. Hamma-Kourbali Y, Bernard-Pierrot I, Heroult M, Dalle S, Caruelle D, Milhiet PE, Fernig DG, Delbe J, Courty J. Inhibition of the mitogenic, angiogenic and tumorigenic activities of pleiotrophin by a synthetic peptide corresponding to its C-thrombospondin repeat-I domain. J Cell Physiol 2008, 214(1):250-259. 10.1002/jcp.21191, 17607711.
28. Dos Santos C, Karaky R, Renoir D, Hamma-Kourbali Y, Albanese P, Gobbo E, Griscelli F, Opolon P, Dalle S, Perricaudet M, et al. Antitumorigenic effects of a mutant of the heparin affin regulatory peptide on the U87 MG glioblastoma cell line. Int J Cancer 2010, 127(5):1038-1051.
29. Bermek O, Diamantopoulou Z, Polykratis A, Dos Santos C, Hamma-Kourbali Y, Burlina F, Delbe J, Chassaing G, Fernig DG, Katsoris P, et al. A basic peptide derived from the HARP C-terminus inhibits anchorage-independent growth of DU145 prostate cancer cells. Exp Cell Res 2007, 313(19):4041-4050. 10.1016/j.yexcr.2007.07.032, 17727841.
30. Martel-Renoir D, Trochon-Joseph V, Galaup A, Bouquet C, Griscelli F, Opolon P, Opolon D, Connault E, Mir L, Perricaudet M. Coelectrotransfer to skeletal muscle of three plasmids coding for antiangiogenic factors and regulatory factors of the tetracycline-inducible system: tightly regulated expression, inhibition of transplanted tumor growth, and antimetastatic effect. Mol Ther 2003, 8(3):425-433. 10.1016/S1525-0016(03)00201-6, 12946315.
31. Elie N, Plancoulaine B, Signolle JP, Herlin P. A simple way of quantifying immunostained cell nuclei on the whole histologic section. Cytometry A 2003, 56(1):37-45.
32. Soulie P, Heroult M, Bernard I, Kerros ME, Milhiet PE, Delbe J, Barritault D, Caruelle D, Courty J. Immunoassay for measuring the heparin-binding growth factors HARP and MK in biological fluids. J Immunoassay Immunochem 2002, 23(1):33-48. 10.1081/IAS-120002273, 11848100.
33. Diamantopoulou Z, Bermek O, Polykratis A, Hamma-Kourbali Y, Delbe J, Courty J, Katsoris P. A Pleiotrophin C-terminus peptide induces anti-cancer effects through RPTPbeta/zeta. Mol Cancer 2010, 9:224. 2936342, 20738847.
34. Said EA, Courty J, Svab J, Delbe J, Krust B, Hovanessian AG. Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin. Febs J 2005, 272(18):4646-4659. 10.1111/j.1742-4658.2005.04870.x, 16156786.
35. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003, 163(4):871-878. 10.1083/jcb.200304132, 2173679, 14638862.
36. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997, 57(9):1814-1819.
37. Jager R, Noll K, Havemann K, Knabbe C, Rauvala H, Zugmaier G. Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell lines. Int J Cancer 1997, 73:537-543. 10.1002/(SICI)1097-0215(19971114)73:4<537::AID-IJC14>3.0.CO;2-6, 9389569.
38. Weber D, Klomp HJ, Czubayko F, Wellstein A, Juhl H. Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. Cancer Res 2000, 60(18):5284-5288.
39. Czubayko F, Riegel AT, Wellstein A. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J Biol Chem 1994, 269(33):21358-21363.
40. Czubayko F, Schulte AM, Berchem GJ, Wellstein A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(25):14753-14758. 10.1073/pnas.93.25.14753, 26208, 8962127.
41. Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Hobel S, Czubayko F, Aigner A. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006, 17(7):751-766. 10.1089/hum.2006.17.751, 16839274.
42. Foehr ED, Lorente G, Kuo J, Ram R, Nikolich K, Urfer R. Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res 2006, 66(4):2271-2278. 10.1158/0008-5472.CAN-05-1221, 16489031.
43. Ulbricht U, Eckerich C, Fillbrandt R, Westphal M, Lamszus K. RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo. J Neurochem 2006, 98(5):1497-1506. 10.1111/j.1471-4159.2006.04022.x, 16923162.
44. Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel PS. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem 2005, 280(29):26953-26964. 10.1074/jbc.M502614200, 15908427.
45. Mathivet T, Mazot P, Vigny M. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?. Cell Signal 2007, 19(12):2434-2443. 10.1016/j.cellsig.2007.07.011, 17904822.
46. Bowden ET, Stoica GE, Wellstein A. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase. J Biol Chem 2002, 277(39):35862-35868. 10.1074/jbc.M203963200, 12107166.
47. Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002, 277(39):35990-35998. 10.1074/jbc.M205749200, 12122009.
48. Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA, Riegel AT, Wellstein A. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene 2009, 28(37):3296-3306. 10.1038/onc.2009.184, 19633684.
49. Ginisty H, Sicard H, Roger B, Bouvet P. Structure and functions of nucleolin. J Cell Sci 1999, 112(Pt 6):761-772.
50. Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, McCormick LM, Bu G, Kadomatsu K. Nuclear targeting by the growth factor midkine. Mol Cell Biol 2002, 22(19):6788-6796. 10.1128/MCB.22.19.6788-6796.2002, 134045, 12215536.
51. Take M, Tsutsui J, Obama H, Ozawa M, Nakayama T, Maruyama I, Arima T, Muramatsu T. Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM). Journal of Biochemistry 1994, 116(5):1063-1068.
52. Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P, Guichard G, Briand JP, Courty J, Hovanessian AG. Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS One 2008, 3(6):e2518.. 2424174, 18560571.
53. Grzelinski M, Steinberg F, Martens T, Czubayko F, Lamszus K, Aigner A. Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia 2009, 11(2):145-156. 2631139, 19177199.
54. Souttou B, Ahmad S, Riegel AT, Wellstein A. Signal transduction pathways involved in the mitogenic activity of pleiotrophin - Implication of mitogen-activated protein kinase and phosphoinositide 3-kinase pathways. J Biol Chem 1997, 272(31):19588-19593. 10.1074/jbc.272.31.19588, 9235965.
55. Dean RA, Butler GS, Hamma-Kourbali Y, Delbe J, Brigstock DR, Courty J, Overall CM. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol 2007, 27(24):8454-8465. 10.1128/MCB.00821-07, 2169415, 17908800.
56. Polykratis A, Delbe J, Courty J, Papadimitriou E, Katsoris P. Identification of heparin affin regulatory peptide domains with potential role on angiogenesis. Int J Biochem Cell Biol 2004, 36(10):1954-1966. 10.1016/j.biocel.2004.02.012, 15203110.